Vildagliptin (VDG)

[Edit]

LAF237; Galvus; Zomelis; Jalra

Vildagliptin (VDG)
Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. There have been case reports of pancreatitis associated with DPP-IV inhibitors. A group at UCLA reported increased pre-cancerous pancreatic changes in rats and in human organ donors who had been treated with DPP-IV inhibitors. In response to these reports, the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-IV inhibitors with pancreatic cancer.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Vildagliptin (VDG) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Vildagliptin (VDG) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Vildagliptin (VDG) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Vildagliptin (VDG) CLIA Kit Customized Service Offer
n/a ELISA Kit for Vildagliptin (VDG) ELISA Kit Customized Service Offer